Oncolink Features

Find My Cancer Drug

Tipos de Cancer / Cánceres Gastrointestinal / Cáncer del Colon y Recto / Opciones Del Tratamiento

Opciones Del Tratamiento

Entendiendo su informe de patología: Cáncer del colon What is a pathology report? A pathologist is a doctor who specializes in diagnosing diseases by examining tissue from the body. You will probably never meet the pathologist, but samples of your colon tissue, removed during surgery or biopsy, will...
Cáncer de dos puntos de la etapa II: ¿Para tratar o no tratar? You would think that deciding whether to have chemotherapy after surgery (adjuvant therapy) in stage II colon cancer would be an easy decision, but in fact, studies have not found a clear answer to this question.
OncoLink Meet the Professor: Weijing Sun, MD discusses developments in colon cancer therapy = Julia Draznin Matlzman, MD, Senior Editor WS = Dr. Weijing Sun Dr. Weijing Sun, Assistant Professor of Medicine at the University of Pennsylvania, the Director of Upper GI and Pancreatic-biliary-hepatic Cancer Group and the Associate...
Progreso clínico en la investigación del cáncer del colon Dr. Bruce J. Giantonio is a practicing oncologist at the University of Pennsylvania and the Executive Officer of the Eastern Cooperative Oncology Group (ECOG). He also served as the study chair for two large ECOG trials evaluating bevacizumab...
A new monoclonal antibody is approved for the treatment of advanced colon cancer Approved On Feb 12th, 2004, the US Food and Drug Administration (FDA) approved a new monoclonal antibody called Cetuximab (Erbitux, formally known as C225, ImClone Systems and Bristol-Myers Squibb Company) for second line treatment of refractory...
Otro golpe para la terapia dirigida The news Genentech won US FDA approval on Thursday (2/24/04) for its greatly anticipated new drug, Bevacizumab (Avastin). Bevacizumab is approved for use in previously untreated metastatic colorectal cancer. The data Approval is based on the...
Eloxatin approved for first line treatment of advanced colorectal cancer Eloxatin approved for first line treatment of advanced colorectal cancer By Julia Draznin Maltzman, MD Approved Eloxatin (oxaliplatin, Sanofi-Synthelabo) along with 5-fluorouracil and leucovorin (5-FU/LV) was recently approved by the...

OncoLink I wish u knew...

Dr. Rebbeck talks about the role of cancer biology and genetics in cancer research and applying that to clinical care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement